Evidence map›Paper›PMID 30813431›Full record

ArticleInternational journal of molecular sciences2019

Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk.

James P Corsetti, Stephan J L Bakker, Ronald T Gansevoort, Eke G Gruppen, Margery A Connelly, Charles E Sparks, Robin P F Dullaart

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

James P CorsettiDepartment of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. james_corsetti@urmc.rochester.edu.
Stephan J L BakkerDepartment of Nephrology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands. s.j.l.bakker@umcg.nl.ORCID 0000-0003-3356-6791
Ronald T GansevoortDepartment of Nephrology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands. r.t.gansevoort@umcg.nl.
Eke G GruppenDepartment of Nephrology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands. e.g.gruppen@umcg.nl.ORCID 0000-0002-5259-9882
Margery A ConnellyLaboratory Corporation of America Holdings (LabCorp), Morrisville, NC 27560, USA. connem5@labcorp.com.
Charles E SparksDepartment of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. charles_sparks@urmc.rochester.edu.
Robin P F DullaartDepartment of Endocrinology, University of Groningen and University Medical Center Groningen, 9700 RB Groningen, The Netherlands. r.p.f.dullaart@umcg.nl.
University Medical Center Groningen · NLUniversity of Rochester · USLabCorp (United States) · US

Funding

Netherlands Heart Fund 2001.005
6 · The paper itself

Abstract

Lipoproteins containing apolipoprotein B modify associations of elevated urinary albumin excretion (UAE) with cardiovascular disease (CVD). Additionally, it is known that elevated UAE alters high-density lipoprotein functionality. Accordingly, we examined whether HDL features might also modify UAE-associated CVD. Multivariable Cox proportional-hazards modeling was performed on participants of the PREVEND (Prevention of Renal and Vascular Endstage Disease) study at the baseline screening with standard lipid/lipoprotein analyses and, three-to-four years later (second screen), with nuclear magnetic resonance lipoprotein analyses focusing on HDL parameters including HDL particle (HDL-P) and apolipoprotein A-I concentrations. These were used with UAE and derived measures of HDL apoA-I content (apoA-I/HDL-C and apoA-I/HDL-P) in risk models adjusted for gender, age, apoB, diabetes, past CVD history, CRP and GFR. Interaction analysis was also performed. Baseline screening revealed significant associations inverse for HDL-C and apoA-I and direct for apoA-I/HDL-C. The second screening demonstrated associations inverse for HDL-P, large HDL-P, medium HDL-P, HDL size, and apoA-I/HDL-P. Significant interactions with UAE included apoA-I/HDL-C at the baseline screening, and apoA-I/HDL-P and medium HDL-P but not apoA-I/HDL-C at the second screening. We conclude that features of HDL particles including apoA-I/HDL-P, indicative of HDL apoA-I content, and medium HDL-P modify associations of elevated UAE with CVD risk.

Indexed as

AdultAgedAlbuminuriaApolipoprotein A-IBiomarkersCardiovascular DiseasesCholesterol, HDLComorbidityC-Reactive ProteinFemaleGlomerular Filtration RateHumansMagnetic Resonance SpectroscopyMaleMass ScreeningMiddle AgedApolipoprotein A-IBiomarkersCholesterol, HDLC-Reactive Proteinalbuminuriaapolipoprotein A-IHDLHDL subfractionsurinary albumin excretion

Identifiers

PMID30813431
PMCPMC6412699
OpenAlexW2918083549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.